APA (7th ed.) Citation

A, K., L, W., I, A., M, G., J, F., G, I., & EW, S. C. (2023). The MIDORA trial: A phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis. RMD open, 9(3), . https://doi.org/10.1136/rmdopen-2023-003317

Chicago Style (17th ed.) Citation

A, Kivitz, Wang L, Alevizos I, Gunsior M, Falloon J, Illei G, and St Clair EW. "The MIDORA Trial: A Phase II, Randomised, Double-blind, Placebo-controlled, Mechanistic Insight and Dosage Optimisation Study of the Efficacy and Safety of Dazodalibep in Patients with Rheumatoid Arthritis." RMD Open 9, no. 3 (2023). https://doi.org/10.1136/rmdopen-2023-003317.

MLA (9th ed.) Citation

A, Kivitz, et al. "The MIDORA Trial: A Phase II, Randomised, Double-blind, Placebo-controlled, Mechanistic Insight and Dosage Optimisation Study of the Efficacy and Safety of Dazodalibep in Patients with Rheumatoid Arthritis." RMD Open, vol. 9, no. 3, 2023, https://doi.org/10.1136/rmdopen-2023-003317.